Director

Serge Saxonov

Chief Executive Officer and Director·10x Genomics, Inc.

About

Serge Saxonov co-founded 10x Genomics and has served as its Chief Executive Officer and a director since July 2012. He also served as the company's President from July 2012 until October 2012.

Before co-founding 10x Genomics, he was Vice President of Applications at QuantaLife, a privately held life sciences company that developed a droplet digital PCR platform, and earlier was Founding Architect and Director of research and development at 23andMe.

He received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.

Since 2012
Age 49
Tenure 14 yrs

Also at 10x Genomics, Inc.

BH Benjamin J. Hindson Chief Scientific Officer, President and Director JS John R. Stuelpnagel Chairman of the Board of Directors AM Alan Mateo Director KP Kimberly J. Popovits Director ST Sarah Teichmann Director SK Sri Kosaraju Director

Roles

Organization Role Dates Details
10x Genomics, Inc. Chief Executive Officer and Director 2012–present Current role
10x Genomics President July 2012 - October 2012 Served as President in addition to CEO during the company's earliest months.
QuantaLife Vice President of Applications May 2010 - April 2012 Privately held life sciences company developing a droplet digital PCR platform.
23andMe Founding Architect and Director of Research and Development June 2006 - May 2010 Privately held personal genomics and biotechnology company.

Related

Company 10x Genomics, Inc. Company hub Person Benjamin J. Hindson Chief Scientific Officer, President and Director Person John R. Stuelpnagel Chairman of the Board of Directors Person Alan Mateo Director Person Kimberly J. Popovits Director Person Sarah Teichmann Director Person Sri Kosaraju Director Person Shehnaaz Suliman Director Person Adam S. Taich Chief Financial Officer Person Randy Wu General Counsel and Secretary Person Eric S. Whitaker Strategic Counsel (former Chief Legal Officer)
Source: 10x Genomics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo